Which responses are possible side effects of inhaled beta2-adrenergic agonists? (select all that apply)
a. Bad taste in the mouth
b. Increased salivation
c. Difficulty sleeping
d. Rapid heart rate
e. Hypotension
f. Diarrhea
ANS: A, C, D
You might also like to view...
A nurse cares for a client who recently completed genetic testing and received a negative result. The client states, "I feel guilty because so many of my family members are carriers of this disease and I am not." How should the nurse respond?
a. "You are not genetically predisposed for this disease but you could still become ill. Let's discuss a plan for prevention." b. "Since many of your family members are carriers, you should undergo further testing to verify the results are accurate." c. "We usually encourage clients to participate in counseling after receiving test results. Can I arrange this for you?" d. "It is normal to feel this way. I think you should share this news with your family so that they can support you."
The patient history plays an important role in assessing the patient's nutritional status. Significant laboratory and clinical findings in the patient with cardiovascular disease include
a. low levels of high-density lipoprotein (HDL) cholesterol and transferrin. b. elevated low-density lipoprotein (LDL) cholesterol and decreased subcutaneous fat. c. elevated sodium levels and a soft, fatty liver on palpation. d. normal triglyceride levels and the presence of S3 on auscultation.
Which of the following best describes what defense mechanisms are?
A. Abnormal coping mechanisms B. Genetically "wired" responses C. Protective devices that reduce anxiety D. All of the above
The FDA issued a safety announcement regarding the use of erythropoiesis-stimulating agents (ESAs) in 2010 with the recommendation that:
1. ESAs no longer be prescribed to patients with chronic renal failure 2. The risk of tumor development be explained to cancer patients on ESA therapy 3. Patients should no longer receive ESA therapy to prepare for allogenic transfusions 4. ESAs be prescribed only to patients younger than age 60 years ___